Phase 3 N=436 Vitamin D Supplementation in Cutaneous Malignant Melanoma Outcome
Cutaneous Malignant Melanoma
Primary: Relapse Free Survival — 41; 32 Participants — p== 0.324
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=997 Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma
Gastric, or Gastroesophageal Junction Adenocarcinoma
Primary: Overall Survival in PD-L1 Positive Participants — 17.2; 12.6 months — p=0.0056
Phase 3 N=920 A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis
Atopic Dermatitis
Primary: Percentage of Participants Achieving a ≥ 90% Reduction From Baseline in Eczema Area and Severity Index Score (EASI 90) and Worst Pruritus Numerical Rating Scale of 0 or…
Phase 3 N=49 A Study to Evaluate ABP 938 and Aflibercept (Eylea®) in Participants With Chorioretinal Vascular Disease (CVD)
Chorioretinal Vascular Disease
Primary: Percentage of IVT Injections Successfully Administered — 100; 100 Percentage of Successful Injections
Phase 3 N=188 Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination for the Treatment of Allergic Conjunctivitis
Allergic Conjunctivitis
Primary: Ocular Itching — 1.176; 1.708; 2.426; 2.362 score on a scale
Phase 3 N=475 Demonstrate Efficacy and Safety of Metastatic Breast Cancer
Metastatic Breast Cancer
Primary: Objective Response Rate — 138; 143 Participants
Phase 3 N=318 ALLEVIATE Trial - A Phase 3 Trial in Subjects With Allergic Conjunctivitis
Allergic Conjunctivitis
Primary: Subject-reported Ocular Itching Score — 52.003; 60.040; 74.657 units on a scale*minutes
Phase 3 N=64 Efficacy of Golimumab in Early Axial Spondyloarthritis in Relation to Gut Inflammation
Axial Spondyloarthritis
Primary: Proportion of Patients Achieving Sustained Clinical Remission — 34 Participants
Phase 3 N=19 Evaluation of Avatrombopag for the Treatment of Thrombocytopenia in Japanese Adults With Chronic ITP
Immune Thrombocytopenia
Primary: Cumulative Number of Weeks of Platelet Response — 13.47 cumulative number of weeks
Phase 3 N=14,727 A Trial to Evaluate the Efficacy and Safety of RSVpreF in Infants Born to Women Vaccinated During Pregnancy.
Respiratory Tract Infection
Primary: Percentage of Infant Participants With Medically Attended Lower Respiratory Tract Illness (MA-LRTI) Cases Due to RSV Occurring Within 90 Days After Birth (Efficacy)…
Phase 3 N=160 Thoracic Epidural Analgesia Versus Rectus Sheath Block Versus Surgeon Infiltration With Liposomal Bupivacaine or Standard Bupivacaine for Post-Operative Pain Control After Cystectomy
Cystectomy
Primary: VAS Score at 48 Hour — 5; 7; 4; 6 score on a scale
Phase 3 N=123 SOLACE Trial - A Phase 3 Trial in Subjects With Non-infectious Anterior-uveitis.
Non-infectious Anterior Uveitis
Primary: Number of Subjects Who Meet Time to Clearance of Anterior Chamber Cells — 25; 24 Subjects
Phase 3 N=803 Efficacy and Safety Study of Rimegepant for the Acute Treatment of Migraine in Japanese Subjects (Japan Only)
Migraine
Primary: Percentage of Participants Who Had Freedom From Pain at 2 Hours Post-Dose — 21.0; 32.4; 13.0 Percentage of participants — p=<0.0001
Phase 3 N=805 Comparison of Efficacy and Safety of Tislelizumab (BGB-A317) Versus Docetaxel as Treatment in the Second- or Third-line Setting in Participants With Non-Small Cell Lung Cancer (NSCLC)
Non-small Cell Lung Cancer
Primary: Overall Survival (OS) in All Participants (Co-primary Endpoint) — 17.2; 11.9 months — p=<0.0001
Phase 3 N=519 A Study to Evaluate eFFIcacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With fibRoMyalgia
Fibromyalgia · Myofascial Pain Syndromes · Muscular Diseases
Primary: Proportion of Patients With ≥30% Pain Improvement — 58; 75 Participants